SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Lili Boulanger — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLili Boulanger
Date of birth1893-08-21
IdentifiersMRN HR-ET025-SYN-TD; SSN (made up) 000-25-7731
Document date1915-08-03
AuthorOdile Marchetti-Rowe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review on maintenance risankizumab. [S]

History of Present Illness

Ms. Boulanger is six months into risankizumab, with two maintenance doses given, the second at home, and the next due in two weeks. She has one or two formed stools a day, no pain, and no extra-intestinal symptoms (Harvey-Bradshaw Index 1). She has regained 5.6 kg since diagnosis. She is composing a new choral work. She asked about having children one day and how her treatment would affect a pregnancy. [S]

ElementDetail
Interval changeTwo maintenance doses; no flares or infections
ActivityHarvey-Bradshaw Index 1
Weight50.6 kg, BMI 19.8
QuestionPregnancy in the future
WorkComposing a new choral work

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or fatigue
GastrointestinalNegativeOne or two formed stools a day
EyesNegativeNo eye pain or redness
MusculoskeletalNegativeNo joint pain
GenitourinaryNegativeRegular periods
PsychiatricNegativeMood good; PHQ-9 3

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugsOne or two tablets up to every 6 hours as neededOral route1914-12-15activeS
Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect40 mg each morning, tapering by 5 mg weeklyOral route1915-01-28 to 1915-03-24completedS
Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction)One infusion every 4 weeks for three dosesIntravenous route1915-02-02 to 1915-04-26completedS
Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12One injection every 8 weeksSubcutaneous route1915-04-27activeS
Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single doseSingle infusionIntravenous route1915-02-02 to 1915-02-02completedS
Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route1915-01-28activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisoneOne tablet daily with foodOral route1915-01-28 to 1915-03-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1915-08-03Body height160cmS
1915-08-03Body weight50.6kgS
1915-08-03Body mass index (BMI) [Ratio]19.8kg/m2S
1915-08-03Systolic blood pressure108mm[Hg]S
1915-08-03Diastolic blood pressure70mm[Hg]S
1915-08-03Heart rate72/minS
1915-08-03Respiratory rate14/minS
1915-08-03Body temperature36.6CelS
1915-08-03Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1915-08-03Hemoglobin [Mass/volume] in Blood13.1g/dL12-15.5 g/dLNormalS
1915-08-03Ferritin [Mass/volume] in Serum or Plasma72ng/mL15-150 ng/mLNormalS
1915-08-03Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma340pg/mL200-900 pg/mLNormalS
1915-08-03C reactive protein [Mass/volume] in Serum or Plasma2mg/L<=5 mg/LNormalS
1915-08-03Calprotectin [Mass/mass] in Stool42ug/g<=50 ug/gNormalS
1915-08-03Albumin [Mass/volume] in Serum or Plasma4.3g/dL3.5-5 g/dLNormalS
1915-08-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 1915-08-03; see the Vital Signs section. [S]

SystemFinding
GeneralWell; BMI 19.8
MouthNo ulcers
AbdomenSoft, non-tender; no mass
SkinNo erythema nodosum; injection sites clear

Problems

ProblemClinical statusVerificationCodeProvenance
Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settledactiveconfirmed K50.80S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed.
Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging bookedresolvedconfirmed R19.7S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D).
Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9)resolvedconfirmed D50.0S — Synthetic finding at presentation; corrected by intravenous iron.
Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dLresolvedconfirmed E44.0S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support.
Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL)resolvedconfirmed E55.9S — Synthetic finding at presentation.
Long-term use of risankizumab, an immunosuppressive biologic, for Crohn diseaseactiveconfirmed Z79.620S — Synthetic treatment status.
Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three daysresolvedconfirmed A08.11S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptoms and Harvey-Bradshaw IndexEvery visitCompleted today1: remission
LaboratoryCRPEvery visitCompleted today2 mg/L
LaboratoryFecal calprotectinAbout six months after starting treatment, then every 3 to 6 monthsCompleted today42 ug/g, normal: biochemical remission
ImagingIleocolonoscopy for endoscopic responseSix to twelve months after starting treatmentOrderedBooked in about two months
LaboratoryHemoglobin, ferritin, and vitamin B12Every 6 to 12 months; B12 yearly with ileal diseaseCompleted todayHemoglobin 13.1 g/dL, ferritin 72, vitamin B12 340 pg/mL
LaboratoryAlbumin and weightEvery visitCompleted todayAlbumin 4.3 g/dL; weight 50.6 kg
LaboratoryLiver enzymes on maintenance risankizumabRoutine after inductionNot indicatedInduction monitoring was completed and normal; no symptoms
SurveyDepression screen (PHQ-9)At least yearlyCompleted todayPHQ-9 3
Self-managementPregnancy planning and contraceptionAt least yearly in women of reproductive ageCompleted todayCounseled; folic acid before conception; preconception review
Medication safetyInfection review and vaccinesEvery visitCompleted todayNo infections since April; influenza vaccine due in the autumn

Goal progress:

Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021); Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2025;23:S1-S60 (2025)

Follow-up: Ileocolonoscopy in about two months. Adult preventive visit in the autumn. Next scheduled visit 1915-10-19: adult preventive visit. [S]